| P50 | author | Milica Pesic | Q53475508 |
| | Ivanka Marković | Q54165998 |
| P2093 | author name string | Sabera Ruzdijić | |
| | Jasna Banković | |
| | Ljubisa Rakić | |
| | Tijana Andjelković | |
| P2860 | cites work | Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions | Q54671388 |
| | Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer | Q62785646 |
| | Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line | Q70275575 |
| | Paradoxical behavior of 6-mercaptopurine as a cytotoxic agent: decreasing cell kill with increasing drug dose | Q71230758 |
| | Cytological effects of sulfur and selenium purine analogues on two transplantable hepatomas and on normal renewing cells in mice | Q71350125 |
| | Monitoring mRNA expression by polymerase chain reaction: the "primer-dropping" method | Q72623932 |
| | Thioguanine substitution alters DNA cleavage mediated by topoisomerase II | Q73127883 |
| | Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells | Q73205086 |
| | DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter | Q73424908 |
| | Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 |
| | Microtubules as a target for anticancer drugs | Q28253993 |
| | Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha. | Q33209927 |
| | Gene expression and the thiol redox state | Q33777925 |
| | Basis for effective combination cancer chemotherapy with antimetabolites | Q33919546 |
| | Pharmacological strategies for overcoming multidrug resistance | Q33997660 |
| | Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. | Q34505103 |
| | Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer | Q36410400 |
| | Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review | Q36444282 |
| | Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 |
| | Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy | Q40158230 |
| | Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. | Q40298181 |
| | The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro. | Q40335896 |
| | Molecular and biological factors in the prognosis of non-small cell lung cancer | Q40376628 |
| | MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. | Q40464073 |
| | Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. | Q40536091 |
| | Cytoprotective features of selenazofurin in hematopoietic cells. | Q40685378 |
| | Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas in vitro | Q40707959 |
| | The role of topoisomerase II alpha and beta in drug resistance | Q40853406 |
| | Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. | Q40942841 |
| | The reversal of multidrug resistance. | Q40965976 |
| | Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. | Q41060917 |
| | Evaluation of three rapid RNA extraction reagents: relevance for use in RT-PCR's and measurement of low level gene expression in clinical samples. | Q41061694 |
| | Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients | Q41328786 |
| | Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. | Q41376224 |
| | Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro | Q41660516 |
| | Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines | Q41740569 |
| | Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. | Q42445479 |
| | Synthesis and in vivo antitumor activity of 2-amino-9H-purine-6-sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides | Q46084000 |
| | Chemotherapeutic characterization in mice of 2-amino-9-beta-D-ribofuranosylpurine-6-sulfinamide (sulfinosine), a novel purine nucleoside with unique antitumor properties | Q46731670 |
| | Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin | Q48079979 |
| P433 | issue | 2 | |
| P921 | main subject | lung carcinoma | Q18556110 |
| | cell line | Q21014462 |
| | doxorubicin | Q18936 |
| | multiple drug resistance | Q643839 |
| P304 | page(s) | 99-110 | |
| P577 | publication date | 2008-05-21 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R) | |
| P478 | volume | 27 | |